GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Coloplast A/S (OCSE:COLO B) » Definitions » Total Liabilities

Coloplast A/S (OCSE:COLO B) Total Liabilities : kr31,940 Mil (As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Coloplast A/S Total Liabilities?

Coloplast A/S's Total Liabilities for the quarter that ended in Mar. 2024 was kr31,940 Mil.

Coloplast A/S's quarterly Total Liabilities increased from Sep. 2023 (kr30,860.00 Mil) to Dec. 2023 (kr33,466.00 Mil) but then declined from Dec. 2023 (kr33,466.00 Mil) to Mar. 2024 (kr31,940.00 Mil).

Coloplast A/S's annual Total Liabilities increased from Sep. 2021 (kr7,673.00 Mil) to Sep. 2022 (kr29,154.00 Mil) and increased from Sep. 2022 (kr29,154.00 Mil) to Sep. 2023 (kr30,860.00 Mil).


Coloplast A/S Total Liabilities Historical Data

The historical data trend for Coloplast A/S's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coloplast A/S Total Liabilities Chart

Coloplast A/S Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,819.00 6,093.00 7,673.00 29,154.00 30,860.00

Coloplast A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28,268.00 28,597.00 30,860.00 33,466.00 31,940.00

Coloplast A/S Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Coloplast A/S's Total Liabilities for the fiscal year that ended in Sep. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=16311+(12222+2203
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+124)
=30,860

Total Liabilities=Total Assets (A: Sep. 2023 )-Total Equity (A: Sep. 2023 )
=48159-17299
=30,860

Coloplast A/S's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=17305+(12340+2165
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+130)
=31,940

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=48140-16200
=31,940

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coloplast A/S Total Liabilities Related Terms

Thank you for viewing the detailed overview of Coloplast A/S's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Coloplast A/S (OCSE:COLO B) Business Description

Traded in Other Exchanges
Address
Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.

Coloplast A/S (OCSE:COLO B) Headlines

No Headlines